Impact of anti-CD200R antibodies (clone OX110) on the growth of EMT6 tumors.
- Zofia Pilch (6240017)
- Katarzyna Tonecka (5949770)
- Marcin Skorzynski (6240020)
- Zuzanna Sas (5368424)
- Agata Braniewska (5368436)
- Tomasz Kryczka (6240023)
- Louis Boon (87167)
- Jakub Golab (88443)
- Linde Meyaard (165282)
- Tomasz P. Rygiel (165274)
Publication date
January 2019
DOI Publisher
Public Library of Science (PLoS)Abstract
(A) EMT6 tumor growth measured as a tumor volume. (B) Example of the gating strategy in flow cytometric analysis of the intratumoral immune cells. (C) Percentage of intratumoral myeloid cells (CD11b+) without neutrophils (Ly6G+). (D) Expression of CD200R in intratumoral immune cells. (E) Percentage of splenic myeloid cells from mice with EMT6 tumors, gating as in the tumors. (F) Expression of CD200R in splenic immune cells. Mice were treated with control or anti-CD200R antibodies (clone OX110). N = 7–8 / group, data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.</p
Add to ORKG